JAZZ (Jazz Pharmaceuticals) חוב לטווח קצר להון

The linear price action on the chart for Jazz Pharmaceuticals (JAZZ), which specializes in neurological drugs, is currently at 0.16. This metric is adjusting under pressure from generic competitors, which the company is offsetting by transitioning to updated formulas. The business relies on the high margins of niche medications, allowing it to cover R&D costs. Meanwhile, strict adherence to temperature controls during transport ensures supply stability.

This indicator measures the share of short-term liabilities within the capital structure, allowing for an assessment of liquidity risk and the company's reliance on the operational refinancing of debts with maturities of up to one year. By analyzing the historical trend of short-term loans relative to equity, an investor can determine the funding stability of the unique Jazz Pharmaceuticals (JAZZ) ecosystem across the neuroscience and oncology segments, supported by exclusive patent rights.